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Background: Progressive neuronal loss in neurodegenerative diseases such as
Parkinson’s disease (PD) is associated with progressive degeneration of associated
white matter tracts as measured by diffusion tensor imaging (DTI). These findings may
have diagnostic and functional implications but their value in de novo PD remains
unknown. Here we analyzed longitudinal DTI data from Parkinson’s Progression Markers
Initiative de novo PD patients for changes over time relative to healthy control (HC)
participants.
Methods: Baseline and 1-year follow-up DTI MRI data from 71 PD patients and 45 HC
PPMI participants were included in the analyses. Whole-brain fractional anisotropy (FA)
and mean diffusivity (MD) images were compared for baseline group differences and
group–by–time interactions. Baseline and 1-year changes in DTI values were correlated
with changes in DTI measures and symptom severity, respectively.
Results: At baseline, PD patients showed significantly increased FA in brainstem,
cerebellar, anterior corpus callosal, inferior frontal and inferior fronto-occipital white
matter and increased MD in primary sensorimotor and supplementary motor regions.
Over 1 year PD patients showed a significantly stronger decline in FA compared to HC
in the optic radiation and corpus callosum and parietal, occipital, posterior temporal,
posterior thalamic, and vermis gray matter. Significant increases in MD were observed
in white matter of the midbrain, optic radiation and corpus callosum, while gray matter
of prefrontal, insular and posterior thalamic regions. Baseline brainstem FA white matter
(WM) values predicted 1-year changes in FA white matter and MD gray matter values.
White but not gray matter changes in both FA and MD were significantly associated with
changes in symptom severity.
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Conclusion: Significant gray and white matter DTI alterations are observable at the time
of PD diagnosis and expand in the first year of de novo PD to other cortical and white
matter regions. This pattern of DTI changes is in line with preclinical and neuroanatomical
studies suggesting that the increased spatial spread of alpha-synuclein neuropathology
is the key mechanism of PD progression. Taken together, these findings suggest that
DTI may serve as a sensitive biomarker of disease progression in early-stage PD.
Keywords: fractional anisotropy, mean diffusivity, Parkinson’s disease, DTI, aging
INTRODUCTION
Diffusion tensor imaging (DTI) of brain grey matter (GM)
and white matter (WM) integrity is a potentially valuable
tool to quantify progressive neurodegeneration in Parkinson’s
disease (PD). In particular, two indices extracted from DTI –
fractional anisotropy (FA) and mean diffusivity (MD) – are
commonly applied to study tissue integrity. FA provides an
anisotropy measure of water diffusion presumably reflecting
preferential directions of fiber orientation whilst MD quantifies
the overall diffusivity reflecting tissue density or its loss in a
longitudinal setting. A key working hypothesis of the underlying
pathophysiological process leading to neurodegeneration and
subsequent clinical decline in PD is that alpha-synuclein
pathology starting in brainstem GM and WM progressively
spreads through connected white matter fiber systems to
cortical GM structures during the course of the disease (Braak
et al., 2003). If DTI alterations in PD indeed reflect the
resulting neurodegenerative process due to alpha-synuclein
pathology, these alterations would also be predicted to show
a progressive spatial spread. Yet, most DTI studies to date
in PD have focused on cross-sectional assessment of single
regions of interest (ROI) such as substantia nigra pars compacta
(SNpc) or basal ganglia. These brain regions have been shown
to be affected in PD and linked with its pathognomonic
motor symptoms, although heterogeneity across studies is high
(see Cochrane and Ebmeier, 2013; Schwarz et al., 2013 for
reviews). However, some whole-brain GM and WM studies
also provided evidence for altered diffusion processes in other
brain structures, including the cortex (Karagulle Kendi et al.,
2008; Mole et al., 2016). Whilst MD has been consistently
shown to be increased in PD, differential findings emerged
with respect to the directionality of FA alterations, with
studies reporting evidence of both increases and decreases in
anisotropy measures (Mole et al., 2016; Atkinson-Clement et al.,
2017).
Only very few studies to date focused on longitudinal
characterization of DTI abnormalities in PD patients (Chan et al.,
2016; Loane et al., 2016; Guttuso et al., 2018; Minett et al., 2018)
and only one evaluated white matter FA and MD alterations
in a de novo PD population (Minett et al., 2018). Additionally,
none of these studies evaluated the potential GM pathology as
evaluated through FA and MD. It therefore remains unclear if
and to what extent FA and MD alterations represent potential
early diagnostic and progression biomarkers in PD patients.
Moreover, it also remains unclear if these alterations reflect
symptom severity or predict disease progression in the early PD
population.
Here we aimed to address the question of the value of GM and
WM FA and MD as early diagnostic and progression biomarkers
in a de novo PD population. We further evaluated the relationship
between these imaging indices and clinical symptoms observed in
the respective patient population.
MATERIALS AND METHODS
Participants
The DTI sample comprised 116 Parkinson’s Progression Marker
Initiative (PPMI) participants who completed 1 year follow-up:
71 with a recent diagnosis of PD and 45 healthy control (HC)
participants. PD and HC groups did not differ with respect
to age or gender distribution, but did differ with respect to
MDS-UPDRS (Movement Disorder Society-sponsored revision
of the Unified Parkinson’s Disease Rating Scale, Goetz et al.,
2008) subscale and total scores, as expected (see Table 1). All
PD patients were treatment naïve at baseline but were allowed
to start PD medication upon need. Only categorical (yes/no)
information was recorded on the respective treatment categories
(L-dopa, dopamine agonists or other PD medication). This study
was carried out in accordance with Good Clinical Practice (GCP)
regulations and International Conference on Harmonization
(ICH) guidelines. PPMI is a large multicenter study and each
site independently received ethics approval of the protocol. All
subjects gave written informed consent in accordance with the
Declaration of Helsinki.
Data Acquisition
Baseline and 1-year follow-up examinations in the PPMI study
included the administration of the MDS-UPDRS (Goetz et al.,
2008). Cardiac-triggered DTI MR sequences were acquired on a
Siemens 3T TIM Trio scanner using a 12-channel matrix head
coil and a two-dimensional echo-planar DTI sequence with the
following parameters: TR/TE = 900/88 ms, flip angle = 90◦, voxel
size = 2 × 2 × 2 mm3, 72 slices, 64 gradient directions with a
b-value of 1000 s/mm2. One non-gradient volume (b = 0 s/mm2)
was also acquired. See (Marek et al., 2011) and the online PPMI
protocol1 for details of the PPMI study and image acquisition,
respectively.
1http://www.ppmi-info.org/wp-content/uploads/2018/02/PPMI-AM-13-
Protocol.pdf
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TABLE 1 | Subject group characteristics.
Group PD patients HC Stats (test value, df, p-value)
N 71 45
Age (mean ± SD) 61.3 ± 9.3 59.6 ± 11 0.9,114,0.371
sex (male/female) 48/23 28/17 0.4,1,0.552
Dominant side (left/symmetric/right) 31/0/40 – –
MDS-UPDRS tot (mean ± SD) 31.5 ± 12.9 2.7 ± 3.4 14.7,114,<0.001
MDS-UPDRS I (mean ± SD) 4.9 ± 3.3 1.9 ± 2.7 5.1,114,<0.001
MDS-UPDRS II (mean ± SD) 5.3 ± 4 0.1 ± 0.5 8.7,114,<0.001
MDS-UPDRS III (mean ± SD) 21.3 ± 8.9 0.7 ± 1.6 15.4,114,<0.001
Delta MDS-UPDRS tot over 1 year (mean ± SD) 2.3 ± 12.3 1.1 ± 3.2 0.6,114,0.546
Delta MDS-UPDRS I over 1 year (mean ± SD) 1.1 ± 3.5 0.5 ± 2.4 1,114,0.304
Delta MDS-UPDRS II over 1 year (mean ± SD) 1.5 ± 3.6 0.2 ± 1.2 2.3,114,0.022
Delta MDS-UPDRS III over 1 year (mean ± SD) −0.3 ± 8.5 0.4 ± 1.6 −0.6,114,0.551
MoCA (mean ± SD) 27.3 ± 2.2 28.3 ± 1.1 −2.8,114,0.007
Delta MoCA over 1 year (mean ± SD, N) −0.6 ± 2.5, 70 −1.2 ± 1.8,45 1.3,113,0.184
On L-dopa at follow-up (yes/no) 20/51 – –
On DA at follow-up (yes/no) 26/45 – –
On others PD med at follow-up (yes/no) 15/56 – –
Resting tremor (yes/no) 55/16 – –
Rigidity (yes/no/unknown) 58/13/0 – –
Bradykinesia (yes/no/unknown) 65/6/0 – –
Postural instability (yes/no/unknown) 2/68/1 – –
df, degrees of freedom; PD, Parkinson’s disease; HC, healthy controls; med, medication; SD, standard deviation; MDS-UPDRS, Movement Disorder Society-sponsored
revision of the Unified Parkinson’s Disease Rating Scale; MoCA, Montreal Cognitive Assessment Test Scoring.
DTI Image Processing
Details of the PPMI DTI pre-processing pipeline including
non-linear distortion correction and FA and MD computation
can be found on the PPMI website2. FA and MD maps were
computed using the TEEM tool as described on the PPMI2.
All maps were downloaded with corresponding structural T1
scans. All further pre-processing was performed using Statistical
Parametric Mapping software (SPM12, Friston et al., 1994). To
improve precision for longitudinal evaluation structural scans
from different time points were first co-registered to a mean
image from those time points for each subject. FA and MD
maps were subsequently co-registered to the respective structural
scans. The structural MRI was segmented into GM and WM
compartments. FA and MD maps were then masked with the
respective binarized compartments to obtain GM and WM FA
and MD estimates and normalized into MNI space based on
structural T1 information. A Gaussian smoothing kernel of
8 mm FWHM (full width at half maximum) was subsequently
applied.
Statistical Analyses
All voxel-wise statistical analyses of the imaging data were
performed using SPM12. Subsequent statistical analyses of the
extracted imaging eigenvariates and clinical data were computed
using SPSS 25 (IBM Corp., Armonk, NY, United States). We
first compared the baseline FA and MD GM and WM maps
2http://www.ppmi-info.org/wp-content/uploads/2011/12/DTI-processing-
Pipeline3.pdf
between PD and HC controlling for the effects of age and
sex using two-sample t-tests. We then tested for group–by–
time interactions (i.e., differential FA and MD trajectories
across PD and HC between baseline and 1-year follow-up)
using a flexible factorial design including the factors group,
time and subject and controlling for sex and baseline age. To
correct for multiple comparisons, an exact permutation based
cluster threshold (p < 0.05) was applied to all voxel-wise
analyses combined with an uncorrected voxel-wise threshold
of p < 0.01 (Dukart et al., 2017). Eigenvariates adjusting for
the effects of covariates of no interest were extracted from the
most significant clusters identified in baseline comparisons and
group–by–time interaction analyses in each contrast. Effect sizes
(Cohen’s d) for the differentiation between PD and HC and
percent changes from baseline (for longitudinal analyses only)
were then computed to estimate the magnitude of observed
alterations. Using these eigenvariates, we then used general
linear models to evaluate whether baseline alterations in FA
and MD observed in PD were predictive of current clinical
severity or 1-year changes in clinical severity as measured by
MDS-UPDRS total or subscale scores while controlling for age,
sex and treatment mode at follow-up (as random effects, for
change prediction only). Similarly, we tested if these baseline
DTI alterations were predictive of 1-year FA and MD alterations
observed in the PD population in group–by–time interaction
analyses controlling for age and sex. Further, we evaluated
using general linear models if changes observed in FA and
MD over time (all entered as covariates into a single model)
were related to changes in function (MDS-UPDRS I, II, III,
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and total scores) while controlling for the random effects of
PD medication status (L-dopa, dopamine agonists or other PD
medication), age and sex. Lastly, we tested if medication may
have affected disease progression effects on FA and MD identified
in the above group–by–time interaction analyses. For this we
computed analyses of variance in PD testing for treatment–by–
time interactions on FA and MD alterations identified in the
longitudinal analyses, controlling for age and sex. We thereby
tested for effects of all three medication types recorded in
the PPMI database (L-dopa, dopamine agonists, and other PD
medication).
RESULTS
Imaging Alterations
At baseline, significantly increased FA was observed in PD
in midbrain, pons and cerebellum, anterior corona radiata,
anterior corpus callosum and left inferior and inferior-occipital
longitudinal fasciculus WM (Cohen’s d = 1.17) (Figure 1
and Table 2). MD was increased in PD in bilateral primary
sensorimotor and supplementary motor GM (Cohen’s d = 0.38)
(Figure 2). No significant differences between PD and HC were
observed in FA GM and MD WM.
In the group–by–time interaction analyses, significant
differences between PD and HC in FA changes over time were
observed in both GM (Cohen’s d = −1.0, HC: 1.6%, PD: −4.1%)
and WM (Cohen’s d = −0.94, HC: 0.0%, PD: −2.3%) (Figure 1
and Table 2). Stronger FA GM decreases were thereby observed
in PD in a cluster covering primarily bilateral parietal, occipital,
posterior temporal and posterior thalamic and vermis regions.
Similarly, stronger FA decreases were observed in PD in the
underlying WM including the left optic radiation and anterior
and middle corpus callosum. For MD, significantly stronger
increases were observed in PD in GM (Cohen’s d = 0.95, HC:
0.5%, PD: 2.8%) and WM (Cohen’s d = 0.8; HC: 0.8%; PD:
3.6%) including, and bilateral medial and lateral prefrontal lobes,
right insula and posterior thalamus GM and the midbrain WM,
left optic radiation and anterior and middle corpus callosum
(Figure 2 and Table 2). These differential longitudinal FA and
MD changes observed in PD were not associated with PD
medication status at follow-up (all p> 0.85).
Associations Between FA and MD and
Function
In PD patients, baseline FA and MD values were neither
significantly associated with baseline symptom severity nor with
changes in symptom severity from baseline to 1-year follow-
up. Baseline FA but not MD alterations in PD significantly
predicted changes in WM FA [F(1,65) = 7.7, p = 0.007] and
GM MD [F(1,65) = 4.1, p = 0.048] which had been observed
in the group–by–time interaction analyses described above
(Figures 3A,B). Higher baseline FA in the brainstem predicted
stronger declines in FA in the posterior corona radiata and corpus
callosum. Importantly, both MD and FA WM changes were
significantly associated with changes in MDS-UPDRS total scores
[FA: F(1,61) = 4.7, p = 0.034; MD: F(1,61) = 4.6, p = 0.036] but not
with the MDS-UPDRS subscale scores (Figures 3C,D). FA and
MD GM changes were not significantly associated with changes
in symptom severity as measured by the MDS-UPDRS.
DISCUSSION
We find significant baseline FA and MD increases in de novo
diagnosed PD patients’ brainstem and subcortical WM and
cortical GM. Within the first year after diagnosis, DTI
abnormalities spread to significant portions of the initially
unaffected cortex and WM. The progression of FA and MD
changes in GM was spatially distinct, with MD changes localized
to the frontal lobe regions, whereas FA changes were localized to
parietal, occipital and posterior temporal regions. WM changes
in both FA and MD co-localized in the posterior corpus callosum
and corona radiata. Both FA and MD changes in WM but
not in GM were clinically relevant, demonstrating significant
correlations with changes in MDS-UPDRS total scores.
Previous research on diffusion alterations in PD have largely
focused on abnormal cross-sectional findings in the substantia
nigra (Cochrane and Ebmeier, 2013; Schwarz et al., 2013) or
ROI (Hall et al., 2016), with a minority of studies adopting
a hypothesis-free, whole-brain approach (for a review see Hall
et al., 2016). With respect to anatomical location of FA and
MD alterations, our cross-sectional and longitudinal findings
agree well with previous studies in more advanced PD reporting
FA and/or MD alterations in the midbrain (Leh et al., 2007;
Cochrane and Ebmeier, 2013; Lenfeldt et al., 2013; Schwarz
et al., 2013), cerebellum (Fling et al., 2013; Vercruysse et al.,
2015), anterior corona radiata (Agosta et al., 2014; Lee et al.,
2014), anterior corpus callosum (Melzer et al., 2012; Agosta
et al., 2014; Chan et al., 2014; Lee et al., 2014; Canu et al.,
2015), left inferior and inferior-occipital fasciculi (Kamagata
et al., 2012; Deng et al., 2013; Lee et al., 2014) and bilateral
primary sensorimotor and supplementary motor areas (Fling
et al., 2013; Vercruysse et al., 2015). Most of these studies
reported decreased FA and/or increased MD in the respective
regions. Importantly, all of these studies focused on more
advanced disease stages. In contrast, a more complex picture
emerged from the present results in the de novo PD population
with respect to the directionality of FA changes. Whilst our
longitudinal data indeed suggest a faster FA decline in PD
as compared to HC, at baseline, we observed only increases
in WM FA in a wide-spread anatomical network including
corticospinal tracts and subcortical WM. These discrepant
findings with respect to FA as compared to results in more
advanced PD patients point to a more complex picture of
underlying pathology in particular at early clinical disease
stages. Importantly, our findings are in line with two out of
three previous studies in de novo PD reporting numerically
increased FA values in white matter (Tessa et al., 2008; Zhang
et al., 2016). FA directionality is often difficult to interpret in
terms of underlying neuropathology. For example a selective
loss of specific fiber directions in crossing-fiber regions may
result in increased FA, whilst a general loss of fibers along
a specific WM tract is expected to result in decreased FA.
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FIGURE 1 | Results of voxel-based morphometry analyses of fractional anisotropy (FA) maps. Bar plots show the eigenvariates extracted from the displayed
significant clusters. Outline colors of the bar plots correspond to the contrast colors of respective clusters. HC, healthy control participant; PD, Parkinson’s disease
patients; GM, gray matter; WM, white matter.
TABLE 2 | Results of voxel-wise analyses of FA and MD maps.
Modality Contrast Anatomical region Cluster size Exact cluster p-value Peak T-value Peak MNI coordinates
WM FA Baseline: PD > HC Midbrain, cortico-spinal, pontine WM
and cerebellum
4118 0.012 4.61 9,−39,−35
Anterior corpus callosum and right
anterior corona radiata
2523 0.030 4.33 20,34,19
Left inferior longitudinal and
inferior-occipital fasciculus
2277 0.037 3.96 −42,−39,−8
Left anterior corona radiata 2009 0.043 3.77 −20,17,3
GM MD Baseline: PD > HC Bilateral primary sensorimotor and
supplementary motor areas
5486 0.047 4.3 4,−9,52
FA GM Interaction:
stronger decrease
in PD
Bilateral parietal, occipital, posterior
temporal, posterior thalamus, vermis
24383 0.006 5.54 −36,−81,1
FA WM Interaction:
stronger decrease
in PD
Left optic radiation, anterior and middle
corpus callosum
5094 0.017 5.45 4,−25,18
MD GM Interaction:
stronger increase in
PD
Bilateral medial and lateral prefrontal,
right insula and posterior thalamus
30012 0.038 5.02 51,10,−5
MD WM Interaction:
stronger increase in
PD
Mid-brain, left optic radiation, anterior
and middle corpus callosum
9260 0.015 5.11 4,−27,16
PD, Parkinson’s disease; FA, fractional anisotropy; GM, gray matter; HC, healthy controls; MD, mean diffusivity; MNI, Montreal Neurological Institute space; WM, white
matter.
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FIGURE 2 | Results of voxel-based morphometry analyses of mean diffusivity (MD) maps. Bar plots show the eigenvariates extracted from the displayed significant
clusters. Outline colors of the bar plots correspond to the contrast colors of respective clusters. HC, healthy control participant; PD, Parkinson’s disease patients;
GM, gray matter; WM, white matter.
Additionally, depending on the original structure composition
a neurodegenerative or a neuroinflammatory process (both
being key contributors if PD) can lead to increases and
decreases in FA. An increased baseline FA in de novo PD
may therefore represent an example of the former situation or
point to a different, more complex underlying neuropathology.
We note that in particular the finding of increased FA in
the corticospinal tract is in line with a recent meta-analysis
reporting this region as only one showing consistently increased
FA across studies (Atkinson-Clement et al., 2017). Moreover,
the significant correlation observed between this increased
baseline FA and longitudinal FA and MD changes suggests
that higher baseline FA is indeed associated with stronger FA
loss and MD increase observed in the first year of follow-
up. These findings support the relevance of this baseline
FA values as a potential predictor of the future spread of
pathology.
Far fewer studies analyzed the longitudinal progression of
DTI signals in PD. Most notably, Zhang et al. (2016) analyzed
PPMI DTI data from 122 PD patients and 50 HCs using
a WM and subcortical region of interest approach (ROI)
based on the JHU-DTI-MNI (Type I WMPM) atlas3. GM DTI
findings were not analyzed, and the authors selected radial
3http://cmrm.med.jhmi.edu
and axial, as opposed to mean, diffusivity measure for their
analyses. Using this ROI approach, PD patients did not differ
from controls in any WM or subcortical region of interest
at baseline. However, in line with the present findings, FA
declined significantly more rapidly in PD patients’ substantia
nigra, midbrain, thalamus, corpus callosum, and frontal white
matter. FA changes in all ROIs were not associated with changes
in MDS-UPDRS scores. We note that the present study’s positive
relationship between FA and MDS-UPDRS changes derived
from global, as opposed to ROI, FA changes. Nevertheless,
the converging findings between the present and Zhang et al.
(2016) studies support the use of DTI to understand WM
changes in de novo PD. Importantly, DTI based measures may
provide complementary information in addition to other imaging
modalities such as volumetric and resting state functional MRI.
On one side, although volumetric MRI is very sensitive to
alterations in regional gray matter volume and cortical thickness
it provides little insight into the underlying gray and white matter
microstructural changes. Such volumetric changes presumably
reflect irreversible damage due to loss of the underlying tissue.
On the other side, resting state functional MRI measures
provide an insight into neural dysfunction, i.e., loss of activity
or connectivity (Dukart et al., 2017). However, such local
functional alterations may also reflect changes in the underlying
structure (i.e., due partial volume effects) or damage of remote
Frontiers in Aging Neuroscience | www.frontiersin.org 6 October 2018 | Volume 10 | Article 318
fnagi-10-00318 October 4, 2018 Time: 15:23 # 7
Taylor et al. Longitudinal DTI in de novo PD
FIGURE 3 | Results of regression analyses between baseline and longitudinal FA and MD values and clinical scores. Significant associations between baseline FA
and longitudinal FA and MD changes are displayed in (A) and (B). Significant associations between longitudinal FA and MD changes and changes in symptom
severity as measured with the MDS-UPDRS (Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale) are displayed in (C)
and (D).
structures, i.e., reduced input (Dukart and Bertolino, 2014).
In that sense, DTI provides a complimentary insight into the
underlying microstructural changes in the respective regions.
As diffusion processes may be affected by any alterations in
tissue organization such as inflammatory, demyelinating or other
processes, DTI provides a potentially more sensitive biomarker
to pick up early microstructural changes in PD prior to tissue
loss detected through volumetric MRI and without confounding
factors related to interpretation of resting state functional
MRI.
Braak et al. (1999) demonstrated that alpha-synuclein-positive
inclusions are present in the axons of PD patients, e.g., the
intramedullary vagal axons from the dorsal motor vagal area,
which itself contained many alpha-synuclein-positive Lewy
bodies. Moreover, Iseki et al. (2001) found that ubiquitin-
positive inclusions in the central nucleus of the amygdala
of patient brains with dementia with Lewy bodies were also
alpha-synuclein and tyrosine hydroxylase positive, suggesting
that the degeneration of terminal axons of affected substantia
nigra neurons were the source of the amygdala pathology in
patients with dementia with Lewy bodies (Iseki et al., 2001).
Consistent with this spreading model, the present study found
that baseline brainstem FA WM values significantly correlated
with both 1-year changes in FA WM and MD GM values. These
findings indicate that DTI may serve as a valuable biomarker
of both disease progression and, extrapolating from Spencer
et al. (2017) preclinical study, also drug efficacy in studies of
disease-modifying agents.
Burke and colleagues suggest that axonal damage in PD
may occur prior to neuronal loss, as described in their
“axonal dying back” model (Burke and O’Malley, 2013;
Tagliaferro and Burke, 2016). The evidence for this claim
derives primarily from various mouse models of PD [e.g., BAC,
heterozygous null gene engrailed1 (En1), and Nurr1 transgenic
mouse models], which all show axonal pathology prior to
neuronal loss (for a review see Tagliaferro and Burke, 2016).
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Correspondingly, in humans, circa 70% of nigrostriatal
dopaminergic terminals are estimated to be lost at the timepoint
of the PD diagnosis, while the level of neurodegeneration has
only reached 30% of substantia nigra dopaminergic neurons
(Cheng et al., 2010). Moreover, a recent study of Alzheimer-
related pathology suggests that DTI abnormalities may portend
the downstream aggregation of pathological proteins: in a
multi-model imaging study with MRI DTI and FTP tau PET,
Jacobs et al. (2018) demonstrated that abnormal MD in the
hippocampal cingulum bundle predicted tau accumulation in
the downstream-connected posterior cingulate cortex 2 years
later in amyloid positive older individuals. We note that as in
synucleinopathies, intraneuronal pathologically aggregated tau
proteins in Alzheimer’s disease are likewise hypothesized to
spread from neuron to neuron along WM tracts (Clavaguera
et al., 2009). Taken together, these findings suggest that DTI may
be used not only as an early marker of alpha-synuclein pathology,
but of future upstream neuronal cell loss and downstream
pathological alpha-synuclein aggregation.
The present study demonstrated baseline brainstem and
cortical abnormalities in de novo PD WM and GM with DTI,
as expected, and a propagation of these abnormalities within
the first year of de novo PD to include large swathes of
cortical regions. Importantly, both the FA and MD changes were
functionally relevant, as evidenced by significant correlations
with changes in MDS-UPDRS total scores. The patterns of
cortical WM neurodegeneration in PD mimicked those described
during normal aging, with stronger FA effects in frontal
and stronger MD effects in parietal regions, which together
suggest a selective vulnerability of these brain regions. In
the context of preclinical PD models suggesting an early
affectation of axons affected by synucleinopathy (i.e., prior
to neuronal loss) (Cheng et al., 2010), the present findings
indicate that DTI-based measures of WM and GM integrity may
represent powerful early biomarkers of disease progression in
de novo PD.
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